Abstract
ObjectivesThis study was designed to investigate the efficacy of antitumor necrosis factor(TNF)(a) agents (etanercept, infliximab, golimumab or adalimumab) in ankylosing spondylitis (AS). MethodsA literature search was done using PubMed, Embaseand Cochrane databases. The reference section of all primary studies was inspected for additional references, and only those reporting the results of a randomized-controlled trial comparing etanercept, infliximab or adalimumab with placebo for patients with AS were included in this analysis. ResultsEleven trials with 1851 patients were included. Compared with placebo, anti-TNF(a) agents was associated with significantly higher rates of Assessment in Ankylosing Spondylitis (ASAS) 20 responders (risk ratio [RR]: 2.45, 95% confidence interval [CI]: 2.13–2.82; P<0.00001), ASAS 50 responders (RR: 3.77, 95% CI: 2.87–4.95; P<0.00001), ASAS 70 responders (RR: 3.25, 95% CI: 1.97–5.35; P<0.00001) and patients with partial remission (RR: 5.39, 95% CI: 3.25–8.93; P<0.00001). In addition, there were more patients with at least 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index score in the experimental groups (RR: 3.07, 95% CI: 2.44–3.86; P<0.00001). Most adverse events in both treatment groups were mild or moderate in severity. ConclusionsAnti-TNF(a) agents is an effective and well-tolerated treatment for reducing clinical symptoms of AS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
